Anticonvulsant activity of DNS II fraction in the acute seizure models

Journal of Ethnopharmacology

Volumn 128, Issue 3, 2010, Pages 600-605

  Raza, Muhammad Liaquat ^a   Zeeshan, Mohammad ^a   Ahmad, Manzoor ^a   Shaheen, Farzana ^a   Simjee, Shabana U ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Delphinium nordhagenii; Diazepam; Epilepsy; Maximal electroshock test; Pentylenetetrazole; Picrotoxin

Indexed keywords

ANTICONVULSIVE AGENT; DIAZEPAM; DNS II FRACTION; HERBACEOUS AGENT; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; DELPHINIUM NORDHAGENII; DRUG DOSE COMPARISON; EPILEPSY; FRACTIONATION; MALE; MOUSE; NONHUMAN; PAKISTAN; RANUNCULACEAE; SEIZURE; TROPICS;

ACETONE; ANIMALS; ANTICONVULSANTS; DELPHINIUM; DIAZEPAM; EPILEPSY; MALE; MELANOMA; MICE; MICE, INBRED STRAINS; PAKISTAN; PENTYLENETETRAZOLE; PHENYTOIN; PICROTOXIN; RANUNCULACEAE; SEIZURES; SKIN NEOPLASMS;

DELPHINIUM; MUS; RANUNCULACEAE;

EID: 77951203673     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.01.054     Document Type: Article

References (48)

1. Benn M.H., Jacyno J.M. Alkaloids: Chemical and Biological Perspectives 1984, vol. 1:153. J. Wiley and Sons, New York.
2. Chadwick D. Better comparisons of antiepileptic drugs: what measures of efficacy?. Pharmacy World & Science 1997, 19:214-216.
3. Coulter D.A., Hugenard J.R., Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Annals of Neurology 1989, 25:582-593.
4. Elger C.E., Bauer J., Scherrmann J., Widman G. Aggravation of focal epileptic seizures by antiepileptic drugs. Epilepsia 1998, 39:S15-18.
5. Freeman F.G., Jarvis M.F. The effect of interstimulation interval on the assessment and stability of kindled seizure threshold. Brain Research Bulletin 1981, 7:629-633.
6. Gilliam F.G. Epilepsy-success in clinical practice: translating trials to practice. European Journal of Neurology 2005, 12:22-29.
7. Guerrini R., Belmonte A., Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998, 39:S2-10.
8. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978, 19:409-428.
9. Langan Y., Nashef L., Sander J.W. Certification of deaths attributable to epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 2002, 73:751-752.
10. Leestma J.E., Walczak T., Hughes J.R., Kalelkar M.B., Teas S.S. A prospective study on sudden unexpected death in epilepsy. Annals of Neurology 1989, 26:195-203.
11. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effects experiments. Journal of Pharmacology and Experimental Therapeutics 1949, 96:99-113.
12. Loscher W., Honack D. The effect of interstimulation interval on the assessment of anticonvulsant drug potency in fully kindled rats. Epilepsy Research 1990, 7:182-196.
13. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Research 1991, 8:171-189.
14. Loscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Research 1988, 2:145-181.
15. Loscher W., Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Research 1994, 17:95-134.
16. Macdonald R.M., Kelly K.M. Antiepileptic drugs mechanism of actions. Epilepsia 1995, 36:S2-S12.
17. Maydell B.V., Wyllie E., Akhtar N., Kotagal P., Powaski K., Cook K., Weinstock A., Rothner A.D. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatric Neurology 2001, 25:208-212.
18. McCabe P.H. New anti-epileptic drugs for the 21st century. Expert Opinion on Pharmacotherapy 2000, 1:633-674.
19. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996, 37:S4-S11.
20. Mucha R.F., Pinel J.P.J. Postseizure inhibition of kindled seizures. Experimental Neurology 1977, 54:266-282.
21. Nielsen E.B., Suzdak P.D., Andersen K.E., Knutsen L.J., Sonnewald U., Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. European Journal of Pharmacology 1991, 196:257-266.
22. Nilsson L., Farahmand B., Persson P.G., Thiblin I., Tomson T. Risk factors for sudden, unexpected death in epilepsy-a case control study. Lancet 1999, 353:888-893.
23. Olafsson E., Hauser W.A., Gudmundsson G. Long-term survival of people with unprovoked seizures: a population-based study. Epilepsia 1998, 39:89-92.
24. Olsen R.W. The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Molecular and Cellular Biochemistry 1981, 39:261-279.
25. Pelletier S.W., Mody N.V., Joshi B.S., Schramma L.C. Alkaloids: Chemical and Biological Perspectives 1984, vol. 2:205. Wiley-Interscience, New York.
26. Perucca E., Meador K.J. Adverse effects of antiepileptic drugs. Acta Neurologica Scandinavica 2005, 181:30-35.
27. Piredda S.G., Woodhead J.H., Swinyard E.A. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. Journal of Pharmacology and Experimental Therapeutics 1985, 232:741-745.
28. Porter R.J, Cereghino J.J., Gladding G.D., Hessie B.J., Kupferberg H.J., Scoville B., White B.J. Antiepileptic drug development program. Cleveland Clinic Quarterly 1984, 51:293-305.
29. Raza M., Shaheen F., Choudhary M.I., Rahman A.-U., Sombati S., Suria A., Rafiq A., DeLorenzo R.J. Anticonvulsant effect of FS-1 subfraction isolated from roots of Delphinim denudatum on hippocampal pyramidal neurons. Phytotherapy Research 2003, 17:38-43.
30. Raza M., Shaheen F., Choudhary M.I., Rahman A.-U., Sombati S., DeLorenzo R.J. In vitro inhibition of pentylenetetrazole and bicuculline-induced epileptiform activity in rat hippocampal pyramidal neurons by aqueous fraction isolated from Delphinium denudatum. Neuroscience Letters 2002, 333:103-106.
31. Raza M., Shaheen F., Choudhary M.I., Sombati S., Rafiq A., Suria A., Rahman A.U., DeLorenzo R.J. Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum. Journal of Ethnopharmacology 2001, 78:73-78.
32. Raza M., Shaheen F., Choudhary M.I., Suria A., Rahman A.-U., Sombati S., DeLorenzo R.J. Anticonvulsant activities of the FS-1 sub fraction isolated from roots of Delphinium denudatum. Phytotherapy Research 2001, 15:426-430.
33. Reina M., Madinvavieta A., Gavin J.A., de la Fuente G. Five diterpenoid alkaloids from Delphinium cardiopetalum. Phytochemistry 1996, 41:1235-1250.
34. Rogawski M.A., Porter R.J. Antiepileptic drugs and pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacological Reviews 1990, 42:223-286.
35. Ryvlin P., Montavont A., Kahane P. Sudden unexpected death in epilepsy: from mechanisms to prevention. Current Opinion in Neurology 2006, 19:194-199.
36. Schachter S.C. Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia 1999, 40:S20-S25.
37. Shackleton D.P., Westendorp R.G., Kasteleijn-Nolst, Trenite D.G., de Craen A.J., Vandenbroucke J.P. Survival of patients with epilepsy: an estimate of the mortality risk. Epilepsia 2002, 43:445-450.
38. Sperling M.R., Feldman H., Kinman J., Liporace J., O'Connor M.J. Seizure control and mortality in epilepsy. Annals of Neurology 1999, 46:45-50.
39. Sperling M.R., Harris A., Nei M., Liporace J.D., O'Connor M.J. Mortality after epilepsy surgery. Epilepsia 2005, 46:49-53.
40. Stone W.E., Javid M.J. Quantitative evaluation of the actions of anticonvulsants against different chemical convulsants. Archive of International Pharmacodynamics and Therapeutics 1979, 240:66-78.
41. Swinyard E.A., Clark L.D., Miyahara J.T., Wolf H.H. Studies on the mechanism of amphetamine toxicity in aggregated mice. The Journal of Physiology 1961, 132:97-102.
42. Swinyard E.A., Kupferberg H.J. Antiepileptic drugs: detection, quantification and evaluation. Federation Proceedings 1985, 44:2629-2633.
43. Swinyard E.A., Woodhead J.H. Experimental detection, quantification, and evaluation of anticonvulsants. Antiepileptic Drugs 1982, 111-126. Raven Press, New York. 2nd ed. D.M. Woodbury, J.K. Penry, C.E. Pippenger (Eds.).
44. Takeuchi A., Takeuchi N. A study of the action of picrotoxin on the inhibitory neuromuscular junction of the crayfish. The Journal of Physiology 1969, 205:377-391.
45. Uijl S.G., Leijten F.S., Parra J., Arends J.B., van Huffelen A.C., Moons K.G. What is the current evidence on decision-making after referral for temporal lobe epilepsy surgery? A review of the literature. Seizure 2005, 14:534-540.
46. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997, 38:S9-S17.
47. White H.S. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999, 40:S2-S10.
48. White H.S., Wolf H.H., Woodhead J.H., Kupferberg H.J. The National Institute of Health anticonvulsant drug development program: screening for efficacy. Antiepileptic Drug Development. Advances in Neurology 1998, vol. 76:1-9. Lippincott-Raven Publishers, Philadelphia.